Description
Olezarsen is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.
The most common side effects include injection site reactions, low platelet counts, and joint pain.
Olezarsen was approved for medical use in the United States in December 2024. The US Food and Drug Administration considers it to be a first-in-class medication.
TRYNGOLZA (olezarsen) injection, for subcutaneous use Initial U.S. Approval: 2024
See full prescribing information: Click Here
Get Access To Tryngolza (olezarsen) Injection In India On Request
Brand Name “Tryngolza” or Generic Name “olezarsen” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or you can call at 9891296838 or WhatsApp at 9891296838
